Table of Contents
Circular RNA is edging toward a modality breakout - and Circio is one of the few players with early pharma validation.
circVec has shown up to 40× higher protein expression and ~75× longer RNA stability in vivo, tackling gene therapy’s core bottleneck: durable expression without vector overload.
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
For clinicians - longer expression could mean fewer doses and lower immunogenicity.
For investors - circVec is emerging as a scarce, IP-strong platform in an RNA dealmaking year. 2026 will be the real test - but the momentum is getting hard to ignore.
At Jefferies, CFO Lubor Gaal gave me the full scoop.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
